Ligand-Binding Assay Overview

Ligand-binding assay (LBA) is a method used to quantify how well a substance binds to a specific target, especially in the evaluation of antibodies. It provides essential evidence on whether an antibody candidate can effectively bind to its intended target. This is particularly crucial for therapeutic antibodies, as their ability to bind to specific targets influences their clinical effectiveness and safety. Consequently, regulatory bodies agencies such as the FDA and EMA commonly require comprehensive LBA profiles as part of the investigational new drug (IND) submission package.

Fig.1 Challenges in LBA development for biologic drugs. (Spengler, Michael & Christof M, 2015)Fig.1 Key challenges for LBAs in the development phases of a biologic drug from discovery to regulatory approval and beyond.1, 3

Ligand-Binding Assay at Creative Biolabs

With our extensive experience and expertise in therapeutic antibody discovery and development, Creative Biolabs provides exceptional LBA services to assist customers in evaluating and confirming the binding properties of your antibodies.

At Creative Biolabs, we specialize in offering cutting-edge LBA services that cater to various therapeutic molecules including peptides, recombinant proteins, monoclonal antibodies, and oligonucleotides. Our assays are not limited to biotherapeutics but also cover anti-drug antibodies, cell therapies, and gene therapies. What sets us apart is our commitment to conducting all assays in GLP-compliant laboratories, ensuring adherence to regulatory guidelines for robust and reproducible results. Our team of experienced professionals will guide you in selecting the most suitable assay reagents and formats, customizing experiment protocols, and delivering comprehensive and reliable outcomes.

Furthermore, we extend our expertise to immunogenicity testing and Fc binding profiling using our state-of-the-art LBA platform. Trust Creative Biolabs for your binding characterization demands and advance your research with assurance.

Fig.2 Our service highlights. (Creative Biolabs Original)Fig.2 Highlights of our LBA services.

Our Ligand Binding Assay Platforms

Creative Biolabs offers a wide range of LBA methods, which include:

  • Conventional methods
Enzyme-linked immunosorbent assay (ELISA), automated ELISA systems, radioimmunoassay (RIA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), immunoradiometric assay (IRMA)
  • Label-free affinity analysis
Surface plasmon resonance (SPR) assay, bio-layer interferometry (BLI) assay, scintillation proximity assay (SPA), LC-MS detection
  • Others
Oligonucleotide hybridization assays, branched chain DNA Assay (bDNA)

Representative Data

Method: Radioimmunoassay (RIA)

Summary: Evaluating drug-target binding kinetics is crucial for determining drug efficacy in vivo. In this study, association binding experiments are conducted to assess the binding kinetics of histamine H1 receptor (H1R) antagonists. The experiments involve competing with radiolabelled probes, providing valuable insights into the binding dynamics of these compounds.

Fig.3 Binding of [3H]mepyramine, [3H]levocetirizine, and [3H]olopatadine to the H1R. (Bosma, et al., 2019)Fig.3 H1R binds to [3H] an antihistamine small molecular agent, [3H] an H1-receptor antagonist, and [3H] a histamine H1 antagonist, respectively.2, 4

Fig.4 Comparing results for radioligand binding assay. (Bosma, et al., 2019)Fig.4 Radioligand binding assay comparing the binding of [3H] an antihistamine small molecular agent and [3H] a histamine H1 antagonist at the H1 receptor in the presence of unlabeled competitors at 25°C.2, 5

Frequently Asked Questions

Q1: What are the requirements for ligand binding assay?

A1: Our LBA services need customers to provide basic information about your testing samples. Leveraging this information, our experts make the most appropriate experiment schemes for your project performance. If you have any specific requirements or questions, please feel free to reach out to our team for personalized assistance.

For more details about our ligand binding assay, please contact us immediately.

References

  1. Spengler, Mark, Michael Adler, and Christof M. Niemeyer. "Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques." Analyst 140.18 (2015): 6175-6194.
  2. Bosma, Reggie, et al. "Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor." Scientific Reports 9.1 (2019): 7906.
  3. under Open Access License CC BY 3.0, without modification.
  4. under Open Access License CC BY 4.0, without modification.
  5. under Open Access License CC BY 4.0. The original image was modified by replacing certain words, and the title was changed to " Radioligand binding assay comparing the binding of [3H] an antihistamine small molecular agent and [3H] a histamine H1 antagonist at the H1 receptor in the presence of unlabeled competitors at 25°C."

For Research Use Only.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2025 Creative Biolabs.
ISO 9001 Certified - Creative Biolabs Quality Management System